Best Pharma Mutual Funds for 3 Months: Should You Invest Now?

The pharma sector is currently one of the strongest-performing themes in the Indian equity market, making pharma-focused mutual funds worth considering for investors with a three-month investment horizon. The Nifty Pharma Index has gained around 16.4% over the past three months, while the Pharma & Healthcare mutual fund category has delivered 13.83% returns over the last one year, outperforming several diversified equity categories. Although short-term volatility cannot be ruled out after the recent rally, the sector’s earnings momentum and defensive characteristics continue to support a positive outlook.

Why is the Pharma Sector Outperforming?

Several structural factors are driving the rally:

Strong earnings growth from leading pharmaceutical companies.
Increasing exports of generic medicines.
Expansion of Contract Development and Manufacturing Organisations (CDMOs).
Rising healthcare spending in India and globally.
Pharma’s defensive nature during volatile market conditions.

These factors have attracted both institutional and retail investors to the sector.

Which Pharma Mutual Funds Have Performed Best?

The top-performing schemes based on one-year returns are:

Fund	1-Year Return
HDFC Pharma & Healthcare Fund Direct	22.67%
Kotak Healthcare Fund Direct	21.84%
WhiteOak Capital Pharma & Healthcare Fund Direct	21.17%
PGIM India Healthcare Fund Direct	17.79%
SBI Healthcare Opportunities Fund Direct	16.42%

HDFC Pharma & Healthcare Fund currently leads the category, while SBI Healthcare Opportunities remains one of the most established healthcare funds with a long performance history.

Sahifund View

For investors looking at the next three months, the pharma sector continues to offer favourable risk-reward potential. The recent strength in the Nifty Pharma Index, improving earnings outlook and sustained institutional interest support the case for selective exposure.

Preferred Funds:

🥇 HDFC Pharma & Healthcare Fund Direct

🥈 Kotak Healthcare Fund Direct

🥉 WhiteOak Capital Pharma & Healthcare Fund Direct

⭐ Long-term diversified choice: SBI Healthcare Opportunities Fund Direct

Should You Invest?

Yes—but selectively. Pharma mutual funds can be considered as a tactical allocation for the next three months, particularly by investors seeking exposure to a sector benefiting from strong earnings momentum. However, these are sectoral funds with very high risk, so exposure should generally be limited to 10–15% of an equity portfolio, with the core portfolio remaining diversified.

Key Takeaway

Pharma remains one of the strongest-performing sectors in 2026. Investors with a three-month investment horizon may consider HDFC Pharma & Healthcare Fund Direct, Kotak Healthcare Fund Direct or WhiteOak Capital Pharma & Healthcare Fund Direct, while SBI Healthcare Opportunities Fund Direct remains a suitable choice for long-term investors seeking an experienced fund manager and an established track record.

Start Your Trading Day with Chanakya Market Dashboard

Instead of visiting multiple market pages, begin your day with the Chanakya Market Dashboard, which brings together all key market insights in one place.